340B program reaches $100 billion in sales, while patients are left behind
PhRMA
JUNE 14, 2023
year-over-year in 2022, continuing a trend in which 340B sales have almost doubled since 2018, outpacing growth of the total U.S. The 340B Drug Pricing Program has grown yet again , exceeding $100 billion in sales in 2022 when 340B-priced medicines are measured at wholesale acquisition cost. Recent data from IQVIA shows 340B grew 12.2%
Let's personalize your content